Peptide Comparison
TabimorelinvsIpamorelin
An investigational oral growth hormone secretagogue that stimulates GH release through ghrelin receptor activation, though development was discontinued due to drug interaction concerns.
A uniquely selective growth hormone booster that tells your pituitary to release more GH without messing with your cortisol or other hormones—making it the 'clean' choice among growth hormone peptides.
At a Glance
Quick
comparison
Dose Range
Tabimorelin
100–500 mg
Ipamorelin
100–300 mcg
Frequency
Tabimorelin
Once daily
Ipamorelin
Multiple times daily
Administration
Tabimorelin
Oral (capsule or solution)
Ipamorelin
Subcutaneous injection
Cycle Length
Tabimorelin
4-6 weeks
Ipamorelin
8-12 weeks
Onset Speed
Tabimorelin
Moderate (1-2 weeks)
Ipamorelin
Moderate (1-2 weeks)
Evidence Level
Tabimorelin
Moderate human trials (Phase 1-2)
Ipamorelin
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Growth Hormone Stimulation
Convenience & Compliance
Selectivity & Safety Profile
GH Selectivity
Recovery Support
Safety Profile
Technical Data
Compound
specifications
Tabimorelin
Molecular Formula
C32H40N4O3
Molecular Weight
528.7 g/mol
Half-Life
Several hours (exact human half-life not published; dose-dependent pharmacokinetics)
Bioavailability
Orally active with dose-dependent bioavailability (increases at higher doses)
CAS Number
193079-69-5
Ipamorelin
Molecular Formula
C38H49N9O5
Molecular Weight
711.85 g/mol
Half-Life
2 hours
Bioavailability
High when injected subcutaneously
CAS Number
170851-70-4
Protocols
Dosing
tiers
Tabimorelin
Ipamorelin
Applications
Best
suited for
Tabimorelin
+Stimulates growth hormone release from the pituitary gland through ghrelin receptor activation
+Orally active—no injections required, making it convenient for daily use
+Dose-dependent growth hormone and IGF-1 elevation at therapeutic doses
+Does not significantly raise ACTH, cortisol, or prolactin at most doses, showing better selectivity than some competing GH-releasing peptides
+Well-tolerated in short-term human studies with generally mild adverse effects
Ipamorelin
Clean GH Boost Seekers
If you want the benefits of increased growth hormone without spiking cortisol or other stress hormones, Ipamorelin is uniquely selective. Unlike GHRP-2 or GHRP-6, it won't raise your cortisol levels even at doses 200 times higher than needed for GH release.
Recovery-Focused Athletes
Ipamorelin shines for athletes who want better recovery between training sessions. The GH boost helps repair muscle tissue faster, and since it doesn't mess with other hormones, you can use it consistently without the rollercoaster effects.
Anti-Aging Enthusiasts
Growth hormone naturally declines as we age, contributing to muscle loss, fat gain, and reduced vitality. Ipamorelin offers a gentle way to restore more youthful GH levels without the risks of actual HGH therapy.
Those Recovering from Steroid Use
Research shows Ipamorelin can help counteract the muscle and bone-weakening effects of glucocorticoid medications. If you've been on steroids for medical reasons, this peptide may help you rebuild what you've lost.
Safety Profile
Side
effects
Tabimorelin
Common
- Headache
- Nausea
- Appetite stimulation
- Dizziness
- Dry mouth
Serious
- Drug-drug interactions via CYP3A4 inhibition
Ipamorelin
Common
- Mild headache
- Injection site reactions
- Water retention
- Increased appetite
Uncommon
- Tingling in hands or feet
- Joint stiffness
Serious
- Allergic reaction
Research Status
Safety
& evidence
Tabimorelin
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Tabimorelin is an oral GHS-R agonist with preclinical and early clinical data indicating dose-dependent appetite stimulation (potentially problematic for weight-conscious users) and transient blood glucose elevation due to GH's insulin-antagonistic effects. No human safety database exists beyond Phase 1/2 studies—efficacy and long-term safety profile in humans remain incompletely characterized. Potential risks include carpal tunnel syndrome (documented with chronic GH therapy), arthralgias, and theoretical tumor growth acceleration, though these are extrapolated from GH physiology rather than directly observed in limited human exposure.
Contraindications
- xActive or history of carcinomas (ghrelin receptor agonists may stimulate growth of certain tumors)
- xConcurrent use of potent CYP3A4 substrates due to risk of dangerous drug-drug interactions
- xUntreated thyroid dysfunction
- xUncontrolled diabetes
Ipamorelin
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
Ipamorelin has shown a favorable safety profile in both animal and human studies. What makes it stand out is its remarkable selectivity—it releases growth hormone without significantly affecting cortisol, ACTH, or other hormones. In clinical trials, it was well-tolerated with mostly mild, temporary side effects. Phase 2 trials in patients recovering from surgery showed no significant safety concerns compared to placebo.
Contraindications
- xActive cancer or history of cancer
- xPregnancy or breastfeeding
- xPituitary disorders or tumors
- xKnown allergy to peptide components
- xChildren and adolescents (growth plates still open)
Decision Guide
Which is
right for you?
Choose Tabimorelin if...
- Stimulating growth hormone production in healthy individuals
- Exploring GH secretagogue mechanisms in research settings
- Patients preferring oral administration over injections
Choose Ipamorelin if...
- Muscle recovery and growth
- Anti-aging and vitality
- Body composition improvement
- Sleep quality enhancement